MICA: The North West England MRC Fellowship Scheme in Clinical Pharmacology and Therapeutics

临床药理学家是医生和科学家，他们的重点是开发和了解现有的和新的药物疗法；他们在学术界、NHS、行业和政府的各种环境中工作。在临床环境中，他们直接与患者合作，参与试验，并调查患者对药物的反应，包括为什么某些患者会对药物产生副作用。英国培养的学术临床药剂师总数很少，必须继续培养更多在临床药理学方面有专长的临床药剂师和其他专家，他们可以在学术界、医疗保健和行业之间工作。2010年，政府认识到，提供高质量的护理和与业界更好的互动需要临床医生熟悉临床药理学的相关做法。利物浦大学和曼彻斯特大学与行业合作伙伴合作，获得了MRC的资金，以满足临床药理学方面的这一未得到满足的需求：英格兰西北部MRC临床药理学和治疗学临床研究培训奖学金计划。该计划允许13名临床研究员(见习医生)从皮肤科、风湿科、儿科等所有医学专科中严格挑选，攻读与临床药理学相关的各种研究课题的博士学位，如药物安全性和分层医学--将合适的药物与合适的患者相匹配。除了他们的研究工作外，研究员还接受了无围墙的工业培训和临床药理学关键方面的模块培训。该计划取得了巨大的成功，发表了56篇科学期刊，发表了21篇会议报告，获得了13个奖项，并与61个NHS信托基金进行了互动。所有研究员还将获得博士学位。我们现在希望与MRC以及4个行业合作伙伴-礼来、诺华、罗氏和UCB Pharma-续签该计划，以任命另外13名研究员。将保留以往成功的形式和结构，以及两所大学的联合领导。对计划的改进包括：增加行业合作伙伴的数量，从而使我们能够涵盖更多的治疗领域，包括癌症；延长招聘过程，让潜在的研究员、他们的主管和行业代表有更多时间来开发具有较强一致性的研究项目；从计划开始就为每个研究员确定一个主要的行业合作伙伴，以便从一开始就建立合作伙伴关系；并在可能的情况下，确保研究员可以在其所在地与行业合作伙伴(S)一起执行其项目的不同方面，最长可达一年。这些变化将加强研究员与行业的培训，并增加行业在个别项目中提供的投入。将会有非常强大的耐心和公众参与(就像目前的计划一样)，患者参与研究提案的规划，一些公共讲座，以及研究员参与曼彻斯特科学壮观活动等活动。研究金计划将在一定程度上培养具有临床药理学专业知识的学者，并帮助优化现有药物的安全、有针对性的处方和人类疾病新疗法的开发。

Clinical pharmacologists are physicians and scientists whose focus is developing and understanding existing and new drug therapies; they work in a variety of settings in academia, the NHS, industry and government. In the clinical setting, they work directly with patients, participate in trials, and investigate how patients respond to drugs, including why certain patients develop side effects to drugs. The total number of academic clinical pharmacologists trained in the UK is small, and there is an imperative to continue to train more clinical pharmacologists and other specialists with expertise in clinical pharmacology who can work between academia, healthcare and industry. In 2010, the Government recognised that the provision of high quality-care and better interaction with Industry requires clinicians to be familiar with the relevant practices in clinical pharmacology. The universities of Liverpool and Manchester, in collaboration with industry partners, were awarded funding from the MRC to address this unmet need in clinical pharmacology: The North West England MRC Clinical Research Training Fellowship Programme in Clinical Pharmacology and Therapeutics. This programme has allowed 13 clinical fellows (high flying trainee doctors), rigorously selected from across all medical specialties e.g. dermatology, rheumatology, paediatrics etc., to study for PhDs on a variety of clinical pharmacology related research topics such as drug safety and stratified medicine - matching the right drug to the right patient. In addition to their research work the fellows received without walls training with industry and modular training in key aspects of clinical pharmacology. The programme has been a tremendous success with 56 scientific journal publications, 21 conference presentations, 13 prizes and interactions with 61 NHS Trusts. All fellows will also get a PhD.We now wish to renew the scheme with the MRC and with 4 industry partners - Lilly, Novartis, Roche and UCB Pharma, to appoint 13 more fellows. The previous successful format and structure will be retained as will joint leadership from the two universities. Refinements to the programme include: increasing the number of industry partners thereby allowing us to cover more therapeutic areas including cancer; lengthening of the recruitment process to give potential fellows, their supervisors and industry representatives more time to develop research projects with strong alignment; identification of a lead industry partner for each fellow from the beginning of the programme to develop a partnership from the outset; ensuring, where possible, that fellows can spend up to one year with the industry partner at their site(s) performing different aspects of their project. These changes will enhance fellows' training with industry, and also increase the input provided by industry in individual projects. There will be very strong patient and public engagement (as in the current scheme) with involvement of patients in the planning of research proposals, a number of public lectures and involvement of fellows at events such as the Manchester Science Spectacular. The Fellowship Programme will go some way to producing academics with expertise in clinical pharmacology and helping to optimise the safe, targeted prescribing of existing drugs and the development of new therapies for human disease.